Investment Rating - The report maintains an "Overweight" rating for the industry [3] Core Viewpoints - The report continues to recommend innovative pharmaceuticals and medical devices along the industry chain [2][7] - The performance of the pharmaceutical sector in September 2025 was weaker than the broader market, with the SW Pharmaceutical Biotech index declining by 1.7% compared to a 0.6% increase in the Shanghai Composite Index [16][22] - The report highlights that the medical service sub-sector performed relatively well, increasing by 1.8%, while medical devices and chemical preparations saw slight declines [22] Summary by Sections - **Investment Recommendations**: The report includes a list of A-share stocks with an "Overweight" rating, including Heng Rui Pharmaceutical, Kelun Pharmaceutical, East China Pharmaceutical, Changchun High-tech, Enhua Pharmaceutical, WuXi AppTec, Tigermed, Lepu Medical, United Imaging Healthcare, and Huatai Medical [7][9] - **Performance Analysis**: The report notes that the monthly portfolio of Guotai Junan Pharmaceuticals outperformed the pharmaceutical index in September 2025, with an average increase of 1.1% compared to a 0.7% increase in the overall pharmaceutical index [12][13] - **Market Comparison**: The report indicates that the pharmaceutical sector's premium level relative to all A-shares is currently at a normal level, with a relative premium rate of 77.5% as of the end of September 2025 [26][28]

Group 1 - The Hong Kong stock market showed positive performance during the National Day holiday, with the Hang Seng Index rising by 0.4%, the Hang Seng Tech Index increasing by 1.3%, and the Hang Seng China Enterprises Index up by 0.2% from October 1 to October 6, 2025. The gains were primarily driven by October 2 [2][5][6] - The MSCI Hong Kong Growth Index fell by 0.3%, while the MSCI Hong Kong Value Index decreased by 0.1% during the same period [5][6] - Key sectors that performed well included steel (+5.60%), electronics (+3.90%), non-ferrous metals (+3.78%), and power equipment and new energy (+3.43%), while agriculture, real estate, food and beverage, and consumer services sectors lagged [5][6] Group 2 - Gold and AI narratives emerged as leading themes during the holiday period, with the U.S. government shutdown impacting market sentiment and driving up COMEX gold and silver prices, benefiting the non-ferrous metals sector in Hong Kong [6][7] - The release of the experimental version DeepSeek-V3.2-Exp on September 29, 2025, contributed to the growth of the AI industry chain in China, leading to significant gains for semiconductor leaders and major internet companies in the Hong Kong market [6][7] Group 3 - As of October 6, 2025, the AH premium rate stood at 129.6%, close to the historical average of 127.1% since 2009, showing a significant decline from over 140% in May [7] - The VHSI index remained stable around 21, indicating a steady market environment, while the average daily trading volume in Hong Kong stocks showed an upward trend [7][8] - Short-term liquidity tightened slightly during the holiday period, as indicated by the 3-month HIBOR and overnight HIBOR rates [7][8] Group 4 - Future prospects for the Hong Kong stock market suggest potential for new highs, contingent on three assumptions: continued inflow of southbound capital, the performance of AI technology and new consumption sectors, and the transmission of monetary policy from broad money to broad credit [8] - The report emphasizes that if these conditions are met, the Hong Kong market could see further upward momentum, supported by a rebound in related industries [8]

Core Viewpoint - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.6% and the Hang Seng Tech Index decreasing by 0.22% [1] Group 1: Market Performance - The pharmaceutical sector faced significant losses, with notable declines in specific companies [1] - Nocera Healthcare and SiHuan Pharmaceutical both dropped over 8% [1] - China Biologic Products and Hansoh Pharmaceutical saw declines exceeding 4% [1]

Group 1 - The stock price of Hansoh Pharmaceutical has decreased by 5.05%, currently trading at 37.6 HKD [1] - The total market capitalization of Hansoh Pharmaceutical is 227.74 billion HKD [1] - Year-to-date, Hansoh Pharmaceutical has experienced a cumulative increase of 120.03% [1]

Group 1 - The US stock market showed mixed performance, with the Dow Jones rising by 0.5%, while the Nasdaq initially increased before falling by 0.3%, and the S&P 500 remained stable [3] - The Golden Dragon Index, which reflects the performance of Chinese concept stocks, declined by 1.2% [3] Group 2 - The Hong Kong stock market performed well last week, with the Hang Seng Index gaining 1,012 points or 3.88%, closing at 27,140 points, while the Tech Index rose by 6.9% to close at 6,622 points [4] - Semiconductor company SMIC (00981.HK) was the best-performing constituent stock, rising nearly 25% over the week, with six other stocks also increasing by over 10%, including Kuaishou (01024.HK) up over 17% and Xinyi Solar (00968.HK) up 14.7% [4] - The worst-performing constituent stock was Pop Mart (09992.HK), which fell by over 4%, with its stock price down more than 25% from its peak [4] - Real estate-related stocks experienced adjustments, with China Resources Mixc (01209.HK) down 3.5%, Longfor (00960.HK) and R&F Properties (01109.HK) down nearly 2.4% and 1.8% respectively, while China Overseas (00688.HK) slightly outperformed peers with a 0.5% increase [4] - Zijin Mining's spin-off, Zijin Gold International (02259.HK), had a strong debut, being quickly included in the Hang Seng Composite Index, with its stock price closing at 120.6 HKD, nearly 90% higher than its IPO price [4] Group 3 - The Hang Seng Index remained above the 10-day moving average (26,600 points), indicating a stable trend, and as long as it stays above this level, the upward trend is expected to continue [5]

恒生科技高开高走后维持在高位盘整，截至目前上涨2.5%。其中中芯国际大涨8.17%，快手上涨615%， 比亚迪电子上涨5.76%，蔚来上涨4.62%，华虹半导体上涨4.44%，百度集团、阿里巴巴等股涨幅均在 3%上方。 恒生工商也有不错表现，截至目前上涨2.1%。其中信义光能大涨9.01%，申洲国际上涨7.92%，中升控 股上涨4.46%，翰森制药上涨4.38%，紫金矿业、石药集团、药明生物等股涨幅均在3%附近。 内房地低开低走大跳水，截至目前下跌2.34%。其中贝壳大跌5.38%，龙湖集团下跌3.45%，建发国际集 团下跌2.85%，华润置地下跌2.24%，越秀地产、九龙仓集团、华润万象生活等股跌幅均在1%上方。 内银行相对弱势但出现了止跌企稳的迹象，截至目前已回到中轴附近。其中重庆农村商业银行大跌 2%，招商银行、农业银行、建设银行等股小幅下跌；民生银行上涨1.7%，交通银行、工商银行、中国 银行等股均小幅上涨。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生指数开盘后直线拉升，截至目前上涨1.41%。其中恒生科技涨幅居前，工商、国指ESG、内石油等 涨幅居前；内房地 ...

Core Points - The Hong Kong stock market closed with the Hang Seng Index rising by 1.61% and the Hang Seng Tech Index increasing by 3.36% [1] - The Hong Kong Tech ETF (159751) rose by 3.17%, while the Hang Seng Hong Kong Stock Connect ETF (159318) increased by 1.11% [1] Sector Performance - Semiconductor products and equipment, as well as metals and mining sectors, showed significant gains [1] - Conversely, passenger airlines and construction products sectors experienced notable declines [1] Individual Stock Movements - Notable gainers included Zijin Mining International, which rose by 14.01%, and SMIC, which increased by 12.7% [1] - Other significant gainers included Kelun-Botai Bio (+9.44%), Lens Technology (+9.19%), Kuaishou-W (+8.57%), and WuXi AppTec (+7.15%) [1] - Decliners included NetDragon, which fell by 6.14%, and Haotian International Construction Investment, which dropped by 11.11% [1] - Dazhong Public Utilities saw a substantial increase of 18.35%, while MIRXES-B rose by 17.1% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 翰森製藥集團有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03692 | 說明 | - | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.00001 | HKD | | 200,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.00001 | HKD | | 200,000 | 本月底法定 ...

Core Points - The Hang Seng Index rose by 1.45% and the Hang Seng Tech Index increased by 2.66% during the midday close [1] - Semiconductor products and equipment, as well as metals and mining sectors, showed significant gains, while passenger airlines and construction products sectors experienced notable declines [1] Individual Stocks Performance - Zijin Mining International surged by 12.02%, followed by SMIC with a 9.3% increase, and Kuaishou-W rising by 6.56% [1] - Other notable gainers include Huahong Semiconductor up by 5.44%, Hengrui Medicine up by 5.29%, and Xinda Biopharmaceuticals up by 4.77% [1] - Conversely, Beike-W fell by 6.21% and Yihua Tong dropped by 6.42% [1] - MIRXES-B saw a significant increase of 13.52%, while Tianqi Lithium rose by 13.04% [1]

Core Viewpoint - The Hong Kong stock market for innovative drug concepts has strengthened, with significant gains in various pharmaceutical companies following the postponement of drug tariffs by the Trump administration [1] Group 1: Market Performance - Companies such as Kelun-Biotech and Gilead Sciences saw their stock prices rise over 8% - Hengrui Medicine increased by over 6% - Companies like Tongyuan Kang Pharmaceutical and Xiansheng Pharmaceutical rose over 5% - Hansoh Pharmaceutical and Innovent Biologics gained over 4% - Companies such as Sihuan Pharmaceutical, Fuxing Pharmaceutical, Shiyao Group, and 3SBio increased by over 3% [1] Group 2: Regulatory Environment - President Trump had previously threatened to impose three-digit tariffs on drug imports starting Wednesday, but the White House indicated that these tariffs may not need to be implemented [1] Group 3: Industry Insights - Pacific Securities released a research report suggesting that attention should be paid to several factors: 1) Changes in Federal Reserve interest rate policies 2) Marginal changes in investment and financing 3) Gradual recovery of overseas demand 4) Sino-US relations and geopolitical factors 5) Class B medical insurance directory and commercial insurance [1]